Fidia Farmaceutici

Abano Terme, Italy

Fidia Farmaceutici

Abano Terme, Italy
SEARCH FILTERS
Time filter
Source Type

Mero A.,University of Padua | Campisi M.,Fidia Farmaceutici | Favero M.,University of Padua | Barbera C.,Fidia Farmaceutici | And 6 more authors.
Journal of Controlled Release | Year: 2014

Osteoarthritis (OA) is characterized by chronic degeneration of joints, involving mainly the articular cartilage and the underlying bone, and severely impairing the quality of life of the patient. Although with limited efficacy, currently available pharmacological treatments for OA aim to control pain and to retard disease progression. Salmon calcitonin (sCT) is a drug which has been shown to have therapeutic effects in experimental arthritis by inhibiting both bone turnover and cartilage degradation and reducing the activities of matrix metalloproteinases (MMP). High molecular weight hyaluronic acid (HA) is used as a lubricant in OA therapy, and, interestingly, HA polymers may normalize the levels of MMP-1, -3 and -13. We demonstrated that sCT rapidly clears from the knee joint of rat animal model, after intra-articular (i.a.) administration, and it induces systemic effects. Here, sCT was conjugated to HA (200 kDa) with the aim of prolonging the residence time of the polypeptide in the joint space by reducing its clearance. An aldehyde derivative of HA was used for N-terminal site-selective coupling of sCT. The activity of sCT was preserved, both in vitro and in vivo, after its conjugation and the i.a. injection of HA-sCT did not trigger any systemic effects in rats. The efficacy of HA-sCT treatment was tested in a rabbit OA model and clear chondro-protective effect was proven by macro- and microscopic assessments and histological findings. Our results indicate that HAylation of sCT increases the size of the polypeptide in a stable covalent manner and delays its passage into the blood stream. We conclude that HA conjugation prolongs the anti-catabolic effects of sCT in joint tissues, including the synovial membrane and cartilage. © 2014 Elsevier B.V.


Montagner I.M.,Instituto Oncologico Veneto IRCCS | Banzato A.,University of Padua | Zuccolotto G.,University of Padua | Renier D.,Fidia Farmaceutici | And 6 more authors.
Urologic Oncology: Seminars and Original Investigations | Year: 2013

Objectives: A previously described hydrosoluble paclitaxel-hyaluronan bioconjugate appears particularly well suited for treatment of superficial bladder cancer because of its in vitro cytotoxic profile against urothelial carcinoma (UC) cell lines and in vivo biocompatibility. The aim of this work was to assess the mechanism of action of the bioconjugate in UC cells. Materials and methods: Expression of CD44 and RHAMM hyaluronan-binding receptors in RT-4 and RT-112/84 UC cell lines, interaction of fluorochrome-labeled bioconjugate with tumor cells, CD44 modulation upon incubation with the compound or free hyaluronan, and caspase activation were assessed by flow cytometry. Cytotoxicity was studied by the MTT assay. Analysis of bioconjugate intracellular localization and effects on β-tubulin organization was carried out by confocal microscopy. Results: The paclitaxel-hyaluronan bioconjugate bound to UC tumor cells entered intracellular compartments through a saturable and energy-dependent mechanism that involved CD44, as assessed by blocking with specific antibody. Upon internalization, the bioconjugate accumulated into lysosomes where the esteric bond between paclitaxel and the hyaluronan moiety was cleaved, leading to cytoplasmic diffusion of the free drug, caspase activation, and disruption of the β-tubulin microtubular mesh with subsequent cell death. Conclusions: Conjugation of paclitaxel to hyaluronan results in a new chemical entity, characterized by selective targeting to polymer receptors on plasma membrane and cell entry through receptor-mediated endocytosis, followed by lysosomal accumulation. Ultimately, the active molecule is released, fully preserving the cytotoxic potential and profile of clinically used free paclitaxel. © 2013 Elsevier Inc.


News Article | November 24, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Global Viscosupplementation Market 2016-2020” new report to its research database. The report spread across 80 pages with table and figures in it. The research analysts forecast the global Viscosupplementation market to grow at a CAGR of 6.23% during the period 2016-2020. About Viscosupplementation Viscosupplementation is a minimally invasive treatment for knee osteoarthritis. It involves the injection of hyaluronic acid into a knee joint to assist the viscous properties of synovial fluid. The procedure increases the joint?s functioning and reduces pain. Intra-articular viscosupplementation with hyaluronic acid is gaining acceptance as it is a non-invasive procedure compared to knee replacement. It is categorized into three product segments ?- single-injection cycle, three-injection cycle, and five-injection cycle. Covered in this report The report covers the present scenario and the growth prospects of the global Viscosupplementation market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products in different regions. The market is divided into the following segments based on geography: - Americas - APAC - EMEA Research report, Global Viscosupplementation Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-viscosupplementation-market-2016-2020/ Key vendors - Sanofi - Anika Therapeutics - Seikagaku - Fidia Farmaceutici - Ferring Pharmaceuticals Other prominent vendors - Allergan - Contipro Biotech - DePuy Synthes - F. Hoffmann-La Roche - Galderma - HTL Biotechnology - Hyaltech - Expanscience Laboratoires - Lifecore Biomedical - Lipo Chemicals - Merz Aesthetics - Mylan - Nordic Drugs - Shandong Freda Biochem - Shanghai Jingfeng Pharmaceutical - Smith & Nephew - TEIJIN PHARMA - TRB Chemedica International Market driver - Fast-growing geriatric population - For a full, detailed list, view our report Market challenge - Threat from substitutes - For a full, detailed list, view our report Market trend - Increasing patient preference for single-injection cycle - For a full, detailed list, view our report Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA INC., introduces newly redesigned packaging for the vaginal hydrating gel, HYALO GYN®. While keeping its current formulation, HYALO GYN®’s new product packaging gives the innovative hydrating gel a dynamic and fresh, feminine look to help make it more appealing to those who may be suffering from vaginal dryness. “Many women often suffer silently from the bothersome symptoms associated with vaginal dryness, but they do not have to. HYALO GYN®, with its unique hyaluronic acid derivative component Hydeal-D®, was made for women to provide long-lasting hydration,” said Aldo Donati, president, FIDIA PHARMA USA INC. “Women trust that HYALO GYN® can provide hydration in a non-hormonal vaginal hydrating gel without a messy buildup or unpleasant order. Keeping its same formulation, HYALO GYN® now features new packaging that exudes a fresher, more feminine look that we believe is more attractive and better aligns with the comfort, hydration and relief that HYALO GYN® provides to women.” In a clinical trial among women who used HYALO GYN® for 30 days, nearly 80 percent reported feeling no messy sensation, and 100 percent of women reported reduction in unpleasant vaginal odor.1 It acts as a moisturizer and lubricant because of the strong hydrating properties of its hyaluronic acid derivative component, Hydeal-D®. Its unique properties allow it to adhere to the vaginal mucosa, enhancing the residence time, thus hydrating and protecting the tissue. HYALO GYN® is a hormone-free, clear, odorless gel that supplements the body’s natural hydrating function and was developed specifically for women whose vaginal lining is not sufficiently hydrated. The carbomer and propylene glycol, combined with the hyaluronic acid derivative, enable HYALO GYN® to achieve its thick, viscous gel form, and the mucoadhesive properties of the product allow it to adhere to the vaginal mucosa, enhancing the residence time, thus hydrating and protecting this tissue.2 HYALO GYN® can be ordered online in the U.S. For product information or to order, please call 1-855-844-0664 or visit www.hyalogyn.com. FIDIA PHARMA USA INC. is a wholly-owned subsidiary of Italian pharmaceutical manufacturer Fidia Farmaceutici S.p.A., an established leader in the hyaluronic acid market segment. FIDIA PHARMA USA INC. is focused on expanding Fidia’s position in the U.S. and Canadian market, while upholding the company’s mission to provide consumers with innovative products that offer quality, safety and performance. FIDIA PHARMA USA INC. is headquartered in Parsippany, N.J. For more information, please visit www.fidiapharma.us. Fidia Farmaceutici S.p.A. is an Italian pharmaceutical company founded in 1946. It is a leader in research and marketing hyaluronic acid-based products, with several applications in the biomedical field, such as rheumatology, orthopaedics, surgery, wound care, tissue repair and dermo-aesthetics. Fidia Farmaceutici is part of the P&R Holding group. The company is located in Italy, with R&D facilities in Abano Terme (Padua) and Noto (Sicily). Fidia has more than 700 employees, and its revenue exceeds €250 million euros. Fidia Farmaceutici S.p.A.’s products are marketed in more than 100 countries, through wholly owned subsidiaries and a comprehensive network of international partnerships and distributors. Thanks to its investment in research, it has created a legacy of products with more than 600 patents to its name. For more information, please visit www.fidiapharma.com. HYALO GYN® is a personal lubricant, for penile and/or vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity and supplement the body’s natural lubrication. This product is compatible with condoms: lubricated/non-lubricated latex, lubricated polyurethane, lubricated natural skin. 1 Tempera, G. Evaluation of the tolerability and efficacy of Hyalgel Vaginal Gel for the treatment of vaginal dryness and irritation, 1998, data on file at Fidia Farmaceutici S.p.A.


PubMed | FIDIA Farmaceutici and University of Milan
Type: | Journal: Molecular neurobiology | Year: 2016

In peripheral neuropathies, such as sensorimotor neuropathies, motor neuron diseases, or the Guillain-Barr syndrome, serum antibodies recognizing saccharide units, portion of oligosaccharides, or oligosaccharide chains, have been found. These antibodies are called anti-glycosphingolipid (GSL) or anti-ganglioside antibodies. However, the information on the aglycone carrying the hydrophilic oligosaccharide remains elusive. The absolute and unique association of GSL to the onset, development and symptomatology of the peripheral neuropathies could be misleading. Here, we report some thoughts on the matter.


PubMed | FIDIA Farmaceutici and University of Milan
Type: Journal Article | Journal: Molecular neurobiology | Year: 2016

Gangliosides (sialic acid-containing glycosphingolipids) are abundant in neurons of all animal species and play important roles in many cell physiological processes, including differentiation, memory control, cell signaling, neuronal protection, neuronal recovery, and apoptosis. Gangliosides also function as anchors or entry points for various toxins, bacteria, viruses, and autoantibodies. GM1, a ganglioside component of mammalian brains, is present mainly in neurons. GM1 is one of the best studied gangliosides, and our understanding of its properties is extensive. Simple and rapid procedures are available for preparation of GM1 as a natural compound on a large scale, or as a derivative containing an isotopic radionuclide or a specific probe. Great research interest in the properties of GM1 arose from the discovery in the early 1970s of its role as receptor for the bacterial toxin responsible for cholera pathogenesis.


Russia Viscosupplementation Market Expected to Grow at a CAGR of 5.3% During 2016 to 2026 Future Market Insights has announced the addition of the “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026" report to their offering. Valley Cottage, NY, February 26, 2017 --( According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products. Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897 The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026. Top Players in Russia’s Viscosupplementation Market Top three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market. Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Valley Cottage, NY, February 26, 2017 --( PR.com )-- Russia’s healthcare infrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people’s eating & drink habits, their proactive lifestyles and the country’s harsh weather conditions. Rising occurrence of joint-related ailments such as knee osteoarthritis in Russia are a result of people performing physical labour in severely cold weather conditions. This has necessitated the adoption of viscosupplementation as an ideal medical procedure for injecting lubricating fluid in bone joints during surgeries. An in-depth analysis of Russia’s viscosupplementation market, conducted by Future Market Insights, projects that demand for three-injection viscosupplementation will gain traction over the next decade.According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products.Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026.Top Players in Russia’s Viscosupplementation MarketTop three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market.Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Click here to view the list of recent Press Releases from Future Market Insights


Russia Viscosupplementation Market Expected to Grow at a CAGR of 5.3% During 2016-2026 Future Market Insights has announced the addition of the "Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment 2016-2026" report to their offering. Valley Cottage, NY, February 24, 2017 --( According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products. Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897 The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026. Top Players in Russia’s Viscosupplementation Market Top three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH andTRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market. Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Valley Cottage, NY, February 24, 2017 --( PR.com )-- Russia’s healthcare infrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people’s eating & drink habits, their proactive lifestyles and the country’s harsh weather conditions. Rising occurrence of joint-related ailments such as knee osteoarthritis in Russia are a result of people performing physical labour in severely cold weather conditions. This has necessitated the adoption of viscosupplementation as an ideal medical procedure for injecting lubricating fluid in bone joints during surgeries. An in-depth analysis of Russia’s viscosupplementation market, conducted by Future Market Insights, projects that demand for three-injection viscosupplementation will gain traction over the next decade.According to Future Market Insights’ recent report, titled “Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026,” nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia’s viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia’s healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products.Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-ru-2897The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia’s ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026.Top Players in Russia’s Viscosupplementation MarketTop three established players in Russia’s Viscosupplementation market include Hyaltech, Croma-Pharma GmbH andTRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country’s viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia’s viscosupplementation market.Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-ru-2897 Click here to view the list of recent Press Releases from Future Market Insights


News Article | February 15, 2017
Site: www.prnewswire.co.uk

Russia's healthcare infrastructure will continue witnessing significant rise in number of orthopaedic patients as several bone & joint-related disorders are likely to be caused by people's eating & drink habits, their proactive lifestyles and the country's harsh weather conditions. Rising occurrence of joint-related ailments such as knee osteoarthritis in Russia are a result of people performing physical labour in severely cold weather conditions. This has necessitated the adoption of viscosupplementation as an ideal medical procedure for injecting lubricating fluid in bone joints during surgeries. An in-depth analysis of Russia's viscosupplementation market, conducted by Future Market Insights, projects that demand for three-injection viscosupplementation will gain traction over the next decade. According to Future Market Insights' recent report, titled "Viscosupplementation Market: Russia Industry Analysis and Opportunity Assessment, 2016-2026," nearly 70% of viscosupplementation revenues amassed across Russia in 2016 were accounted by three-injection viscosupplementation. The report estimates that the Russian viscosupplementation market incurred revenues worth over RUB 1.13 billion (US$ 19 million) in 2016. Registering a steady increment at 5.3% CAGR, Russia's viscosupplementation revenues are expected to reach RUB 2.02 billion (US$ 34 million) by the end of 2026. With higher demand for three-injection viscosupplementation, Russia's healthcare industry leaders will continue to extend production of three-injection viscosupplementation products as opposed to single injection and five-injection viscosupplementation products. The report also establishes projections regarding the end-use of viscosupplementation in Russia. Hospitals across the country will account for just above RUB 1.24 billion (US$ 21 million) revenues by the end of projection period. Within this, the demand for viscosupplementation will remain considerably higher in hospitals with capacity of more than 500 beds. End-use of viscosupplementation in Russia's ambulatory surgical centres (ASCs) will remain nascent, while revenues accounted by orthopaedic clinics are expected to surpass RUB 595 million (US$ 10 million) through 2026. Preview Analysis on Russia Viscosupplementation Market Segmentation By Product Type - Single Injection, Three Injection, Five Injection Viscosupplementation; By End Use - Hospitals (500+ Bedded, 250-500 Bedded, Less Than 250 Bedded), Ambulatory Surgical Centres, Orthopaedic Clinics: http://www.futuremarketinsights.com/reports/russia-viscosupplementation-market Top three established players in Russia's Viscosupplementation market include Hyaltech, Croma-Pharma GmbH and TRB Chemedica. The market is fragmented with small players holding substantial market share. While Hyaltech, Croma-Pharma GmbH and TRB Chemedica collectively dominate with more than half of the country's viscosupplementation revenues. International players such as Sanofi, Ferring Pharmaceuticals and Fidia Farmaceutici spa have low share as compared to the other players, Anika Therapeutics has recently launched their viscosupplementation product in Russia's viscosupplementation market. Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.


Schiavinato A.,Fidia Farmaceutici | Whiteside R.A.,University of Guelph
Clinical Biomechanics | Year: 2012

Background: Intra-articular injection of hyaluronic acid based therapies is gaining popularity as a treatment option for non-operative management of patients with symptomatic osteoarthritis. Although there is an abundance of evidence for both biological and mechanical mechanisms of joint protection by hyaluronic acid, one clear intention of viscosupplementation is to reduce friction and wear by providing an extrinsic lubricant. We tested the in vitro friction response of a novel hyaluronic acid derivative that presents amphiphilic features to promote adhesion to the cartilage surface and thereby improve cartilage lubrication. Methods: Migrating Contact Area and Static Contact Area friction tests were conducted on bovine articular cartilage to assess the efficacy of two lubricants, a chemically modified amphiphilic hyaluronic acid and synovial fluid from a healthy joint, as well as a phosphate buffered saline negative control. Findings: No differences in lubrication (P = 0.34) were evident between the three test articles during the Migrating Contact Area test, which represents articulation of healthy articular cartilage. The modified hyaluronic acid presented an equilibrium friction coefficient 2.8 times less than that of the synovial fluid (P ≤ 0.0005) and five times less than that of the PBS control (P ≤ 0.0001) during the Static Contact Area test, representing a mixed lubrication condition. Interpretation: The present study demonstrated that a chemically modified amphiphilic hyaluronic acid can provide equivalent lubrication to synovial fluid during articulation of loaded healthy articular cartilage and can provide superior lubrication as indicated by a lower coefficient of friction than synovial fluid under loading conditions potentially associated with cartilage wear. © 2011 Elsevier Ltd. All rights reserved.

Loading Fidia Farmaceutici collaborators
Loading Fidia Farmaceutici collaborators